Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah it’s completely legal. Do it for you and your wife if you have one. 6 K each for 2019. 2018 was 5500.
Ha. I’m glad it was posted. So much potential over the next few weeks. Vascepa making guidelines would be my number one on the wish list. Everything falls into place after that.
Why would they not PR this?
Cheers to all of our gains this year. Anyone else just file their tax returns. Gov just got a shitload of money from my amrn gains last year and is going to get even more this year when we go boom! so be it.
Thanks for doing that.
Appreciate it. Thanks. We will have better idea of sales trajectory end of March but we can definitely explode at any point and get way above.
What do we need scripts to get to on the weekly to hit 350 million. Any idea
Not sure what they mean by the primary prevention part. Maybe a subgroup within it showed benefit. certainly possible.
Why would some insiders according to this hold 0 shares. Is that common with insiders in other companies ?
I agree
Gota be q1 or we have the unluckiest stock in the world.
What’s the magic number of new scripts we need to hit 350 Million? I am sure a long ways away but this seems like we would be on pace.
Thanks Sam
There’s definitely a lot of data not presented yet.
Well stated. Point number 6 is not to be overlooked. That was major.
There’s just every reason to buy this now and I don’t think there’s a better company to do it then PFE. Every month BP waits to buy amrn out will cost them billions in unrealized potential revenue
Will c.
What study are you referencing for amrn to go after NASH? It seems like we aren’t there yet unless I haven’t seen something. Thanks.
You need a trial for the combo ?
Thanks for taking a look. Appreciate it.
No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
trial with epadel.
Just read it. I am not a NASH expert. I am trying to learn more about it to see if amrn has a place here.
Do we think this failed due to not enough EPA? Maybe.
Nominated. I’m pretty sure this amrn story and message board is more interesting than my day job by far.
Let’s keep this rally going.
How does anyone know PFE rumored to buy amrn? Just curious how the street insider article finds that out and it gets tweeted. Wish I knew how real it was. Either way. long and strong. Nice day for the board.
https://clinicaltrials.gov/ct2/show/NCT02719327
2021 results. Agree. It would make sense we show benefit here. This is a huge unmet need. The dementia space is dying for any therapy that can remotely help.
That’s good Thanks.
Interesting why amrn never includes the other indications in their presentations or even mentions them.
I’d love to still be holding this for the Alz indication in couple years. I’m in for triple digits stock price which can possibly happen with cardiac indications alone if and when they can penetrate this market.
Agreed. I think we beat estimates by far. There’s so many catalysts in 2019 no one in their right mind can provide a forecast to this company. Hold tight. Obviously we want to be rich overnight but we have a pot of gold here we just don’t know when we can cash in.
FISHing for the Miracle of Eicosapentaenoic Acid
John J.P. Kastelein, M.D., Ph.D., and Erik S.G. Stroes, M.D., Ph.D.
January 3, 2019
N Engl J Med 2019; 380:89-90
DOI: 10.1056/NEJMe1814004
This article has no abstract; the first 100 words appear below.
Bhatt et al. report in the Journal the results of the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT), in which 8179 high-risk patients who had elevated triglyceride levels and had been receiving statin therapy were randomly assigned to receive 2 g of icosapent ethyl twice daily or placebo containing mineral oil.1 The patients were enrolled mostly on the basis of secondary prevention (71%), and almost 60% had diabetes. At baseline, low-density lipoprotein (LDL) cholesterol levels were well controlled among the patients (median value, 75.0 mg per deciliter [1.94 mmol per liter]), and triglyceride levels were slightly elevated (median . . .
A commentary article about reduce it. Appreciates the big results of reduce it despite the authors getting paid by azn and other biotech firms creating bias.
Btw NEJM has 552 K followers on twitter. Hopefully these posts and articles spark some future scripts.
Yeah so we will have PP on label. Also, on your last point, subgroups in the PP cohort can show statistically significant results despite the overall group showing a trend without significance.
I think your a little mistaken here.
Amrn will get primary prevention on the label. They ran a large trial that was grossly positive. You can’t subgroup out the 29 percent of pts in the trial subgroup and say bc it wasn’t as good as the other 70 percent that it isn’t beneficial. It was still beneficial with a trend in both primary endpoint and secondary endpoint for primary prevention group. The trial wasn’t designed for that evaluation. There was a reduction in events in primary prevention group for the primary endpoint of 12.2 percent events vs 13.6 percent events in placebo. Hazard ratio 0.88 (CI 0.7-1.1). It just barely crosses one making it a trend and not statistically significant obviously.
No doubt primary prevention is on label. JT gave no doubt of that on last conf call as well. Any study in this space has been similar. Again you can’t eliminate the perceived benefit by looking at a smaller subgroup that is not powered to be looked at by itself.
Agree JL and hoping for that.
There’s so much to look forward to with amrn. It’s always been painful but rewarding.
Nice post amongst the rather boring board of late. Boring not because of the posters just because there’s been really not much to talk about.
I think q1 is our next moment to get excited for. This European news is fairly bullish. When we first invested in amrn many years ago we could only wish multiple publications would discredit fish oil supplements and now Europe concluding combo epa/dha has no benefit. Matter of time until stock price reflects amrn.
All I can say is I don’t understand how the fda can justify not giving us an expedited review. Even this will take a long time but Vascepa should get it. JT is being conservative saying he’s not expecting it.
True. Damn fda.
The combo pill would be so nice.
What’s the regulatory pathway for a combo drug as in how early can we see it ?
Thanks.
You know when amrn will announce their revenue guidance for next year?
Interestingly JT commented at his recent Jeffries meeting that AZN poses as competition but that the study is delayed and likely won’t read out to 2020. Amrns position on AZN agree is very confusing. This was the first year I heard them say how they believe their patents are strong and helped keep AZN from marketing (stated in fall). Then JT says what he said at recent conf call and your left thinking is AZN going to be able to market their drug or not. Time will tell and if only if the trial is positive anyway.
The Afib argument is garbage. the ARR is a joke considering the stroke benefit. Non issue for any physician.
Thanks. Appreciate it.
Excuse my Ignorance here
Is it strategic for amrn not even to pursue an expanded label ?
If insurances pick this up like crazy as Dr Bhatt or some cardiologist already mentioned, then what does a label add ? The argument can be more physicians will prescribe it ? However we prescribe meds all the time off label probably more off label then on label. I don’t have to deal with insurance companies bc I work in an ER setting. Again if we get a billion in sales next year without a label what does the label add? We already can speak truthful to doctors about it with 1st amendment win. Idk just a thought ?
Welcome back. It’s been rough. The 0.1 percent chance happened. Only way. Best news of all time and we crashed.
Summary is essentially the mineral oil placebo was picked on but has no basis. Dr Bhatt explained it, NEJM explained it. FDA and amrn have spa and agreed on mineral oil. Also other studies had raised in LDL in placebo group it’s not unique to amrn placebo group.
Then the threat of this class action law suit based on that seeking alpha article was nail in coffin even though it is BS.
Bottom line is bears effectively casted doubt of placebo causing anti statin effects.
I think only saving grace now is sales to align the thoughts of physicians/investors with Wall Street that doesn’t think we will get label/and sales. One way which would help would be getting into AHA guidelines ASAP.
Again welcome back.
Cost savings Explained-
Savings is directly related to number needed to treat. That’s what everyone looks at.
NNT is 21 for Vascepa. Outstanding. Unbelievable. Most drugs not even close to this.
BP control NNTs
1 in 125 were helped (prevented death)
1 in 67 were helped (prevented stroke)
1 in 100 were helped (prevented heart attack*)
Get lost. End of story.
Did u read NEJM. The study and supplements.
Or see Dr bhatt YouTube post he explains this issue more than is even needed